Indian CRO Syngene sets up Amgen R&D center in Bangalore

Syngene International, one of Asia’s biggest CROs and part of Biocon, has commissioned a new drug discovery and development center for Amgen in its native town of Bangalore, India.

The Syngene Amgen Research and Development Center (SARC) is now the fourth R&D hub coming out of Syngene, adding to its centers for Bristol-Myers Squibb ($BMY), Abbott Nutrition ($ABT) and Baxter ($BAX).

Described as “state-of-the-art,” its latest offering will be made up of around 100 Syngene scientists who will work hand-in-hand with Amgen researchers in India and around the world to help find and develop new meds.

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

Jonathan Hunt, CEO at Syngene, said: "We are delighted to announce the establishment of our dedicated R&D center for Amgen. Bringing together into one place, the range of activities we conduct on behalf of Amgen indicates the strategic nature of our relationship and also reflects the ability of Syngene’s scientific teams to deliver world-class science towards our partners’ R&D programs in both biotechnology and small molecule medicines.”

This further cements long-running ties between the two that see them already working on a series of discovery and development projects.

“With the establishment of SARC, this association now extends into a multi-discipline collaboration spanning capabilities in medicinal and process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research, and pharmaceutical development,” the CRO said in a statement. 

Suggested Articles

IQVIA is still steering around COVID-19 roadblocks with its R&D business still posting a loss, but other segments are recovering.

After snapping up contract research organization Covance for $6.5 billion five years ago, LabCorp is now looking to change the makeup of its drug dev

Siteless Californian trial company Science 37 has penned a new deal with Signant Health for digital studies focused on CNS work.